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GPCRNanoluciferase (NanoLuc) is a newly developed small luciferase reporter with the brightest bioluminescence to
date. In the presentwork,we developedNanoLuc as a sensitive bioluminescent reporter tomeasure quantitatively
the internalization of cell membrane receptors, based on the pH dependence of the reporter activity. The G
protein-coupled receptor RXFP3, the cognate receptor of relaxin-3/INSL7, was used as a model receptor. We
ﬁrst generated stable HEK293T cells that inducibly coexpressed a C-terminally NanoLuc-tagged human RXFP3
and a C-terminally enhanced green ﬂuorescent protein (EGFP)-tagged human RXFP3. The C-terminal EGFP-tag
and NanoLuc-tag had no detrimental effects on the ligand-binding potency and intracellular trafﬁcking of
RXFP3. Based on the ﬂuorescence of the tagged EGFP reporter, the ligand-induced RXFP3 internalization was
visualized directly under a ﬂuorescence microscope. Based on the bioluminescence of the tagged NanoLuc
reporter, the ligand-induced RXFP3 internalization wasmeasured quantitatively by a convenient bioluminescent
assay. Coexpression of an EGFP-tagged inactive [E141R]RXFP3 had no detrimental effect on the ligand-binding
potency and ligand-induced internalization of the NanoLuc-tagged wild-type RXFP3, suggesting that the mutant
RXFP3 and wild-type RXFP3 worked independently. The present bioluminescent internalization assay could be
extended to other G protein-coupled receptors and other cell membrane receptors to study ligand–receptor
and receptor–receptor interactions.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Nanoluciferase (NanoLuc) is a newly developed small luciferase
reporter (171 amino acids, 19 kDa) with the brightest bioluminescence
to date [1]. It emits a long half-life glow-type bioluminescence using
furimazine and molecular oxygen as substrates, in an adenosine
triphosphate-independent manner. NanoLuc has several advantages
over conventional luciferase reporters, such as high speciﬁc activity,
small size, high stability and lack of posttranslational modiﬁcations,
rendering it an ideal bioluminescent reporter in biological sciences [2].
In a recent study, we used NanoLuc as a sensitive reporter to monitor
the internalization of the iron efﬂux transporter ferroportin based on
the pH dependence of the NanoLuc activity [3]. In the present work,
we tested whether NanoLuc can be used as a general quantitative
reporter to monitor the internalization of other cell membrane
receptors. A G protein-coupled receptor (GPCR), RXFP3, was used as a
model receptor, because GPCRs are the largest group of cell membrane
receptors and play critical biological functions.ch, College of Life Sciences and
ai 200092, China. Tel.: +86 21
o).The relaxin family peptide receptor RXFP3 is the cognate receptor of
relaxin-3 (also known as INSL7), a neuropeptide belonging to the
insulin/relaxin superfamily [4–7]. The relaxin-3/RXFP3 system is involved
in the regulation of food intake, stress response, as well as arousal and
exploratory behaviors [8–14]. In vitro, relaxin-3 can also bind and acti-
vate the relaxin-family peptide receptor RXFP1 [15] and RXFP4 [16]
whose endogenous ligands are relaxin [17] and INSL5 [18], respectively.
In the present work, we generated stable HEK293T cell that
inducibly coexpressed a NanoLuc-tagged RXFP3 and an EGFP-tagged
RXFP3 and demonstrated that ligand-induced RXFP3 internalization
could be measured quantitatively based on the bioluminescence of the
tagged NanoLuc reporter. We also demonstrated that an inactive
RXFP3 mutant had no detrimental effect on the ligand-binding and
internalization of the wild-type RXFP3, suggesting that the mutant
and the wild-type RXFP3s worked independently.
2. Materials and methods
2.1. DNA manipulation
The coding region of the C-terminally NanoLuc-tagged human
RXFP3 (RXFP3-Luc) was PCR-ampliﬁed, using the previously generated
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pGM-T vector (Transgene, Beijing, China). After conﬁrmation by DNA
sequencing, the coding region of RXFP3-Luc was released from the
pGM-T vector by digestion with restriction enzymes ApaI and BamHI,
and then ligated into the multiple cloning site 1 of vector pTRE3G-BI
(Clontech, Mountain View, CA, USA) pretreated with the same restric-
tion enzymes, resulting in the construct pTRE3G-BI/RXFP3-Luc.
The coding region of human RXFP3 (without the stop codon) was
PCR-ampliﬁed using pcDNA6/RXFP3 [19] as the template, digested by
restriction enzymes KpnI and AgeI, and then ligated into a previously
generated pGM-T/EGFP vector, resulting in the construct pGM-T/
RXFP3-EGFP. After conﬁrmation by DNA sequencing, the coding region
of the C-terminally EGFP-tagged RXFP3 (RXFP3-EGFP) was released
from pGM-T/RXFP3-EGFP by digestion with restriction enzymes KpnI
and NdeI, and then ligated into the multiple cloning site 2 of pTRE3G-
BI/RXFP3-Luc, resulting in a coexpression construct of pTRE3G-BI/
RXFP3-Luc:RXFP3-EGFP. Site-directed mutagenesis of RXFP3-EGFP
was carried out using the QuikChange approach based on the construct
pGM-T/RXFP3-EGFP. After conﬁrmation by DNA sequencing, the coding
region of [E141R]RXFP3-EGFPwas released by digestionwith restriction
enzymes KpnI and NdeI, and then ligated into multiple cloning site 2 of
the construct pTRE3G-BI/RXFP3-Luc, resulting in a coexpression
construct of pTRE3G-BI/RXFP3-Luc:[E141R]RXFP3-EGFP. Site-directed
mutagenesis of RXFP3-Luc was carried out using the QuikChange
approach based on the construct pGM-T/RXFP3-Luc. After conﬁrmation
by DNA sequencing, the gene of [E141R]RXFP3-Luc was released from
the pGM-T vector by restriction enzymes ApaI and BamHI, and then
ligated into the multiple cloning site 1 of the construct pTRE3G-BI/
RXFP3-Luc:RXFP3-EGFP in which the gene of RXFP3-Luc had been
removed from the multiple cloning site 1 by ApaI and BamHI, resulting
in the coexpression construct of pTRE3G-BI/[E141R]RXFP3-Luc:RXFP3-
EGFP. To generate the construct of pTRE3G-BI/RXFP3-HA-Luc, a small
nucleotide linker encoding the HA-tag was inserted into the construct
pTRE3G-BI/RXFP3-Luc after it was treated by restriction enzyme AgeI,
and the correct colonywas identiﬁed byDNA sequencing. A small nucle-
otide linker encoding the Flag-tag was inserted into the construct of
pGM-T/RXFP3-EGFP after it was treated by restriction enzyme AgeI.
After conﬁrmation by DNA sequencing, the gene of RXFP3-Flag-EGFP
was released from the pGM-T vector by restriction enzymes KpnI and
NdeI, and then ligated into the multiple cloning site 2 of the construct
pTRE3G-BI/RXFP3-HA-Luc, resulting in the coexpression construct
pTRE3G-BI/RXFP3-HA-Luc:RXFP3-Flag-EGFP.
2.2. Generation of stable HEK293T cells
For transient transfection, HEK293T cells in a 35-mm dish were
cotransfected with the RXFP3 expression construct and an expression
control vector pCMV-Tet3G (Clontech), using the Xfect transfection
reagent (Clontech) according to the manufacturer's instructions. The
transiently transfected cells were cultured for approximately 10 days
with normal passages. To induce expression of RXFP3-EGFP and RXFP3-
Luc, the cells were treated by doxycycline (50 ng/ml) overnight. There-
after, the cells, in two 10-cm dishes, were trypsinized and subjected to
ﬂuorescence-activated cell sorting (FACS) according to the ﬂuorescence
of the tagged EGFP reporter. The positive cells were pooled together and
continuously cultured for approximately 10 dayswith normal passages.
Thereafter, the cells were treated with doxycycline (50 ng/ml) over-
night and subjected to a second round of FACS selection according to
the ﬂuorescence of the tagged EGFP reporter. The positive cells were
pooled together, continuously cultured and used as stable cells for
subsequent experiments.
2.3. Recombinant preparation and chemical labeling of relaxin-3
A fully active, easily labeled relaxin-3 was prepared through recom-
binant expression of a single-chain precursor in Escherichia coli andsubsequent enzymatic conversion, according to our previous proce-
dure [19]. The mature easily labeled relaxin-3 was puriﬁed to homoge-
neity by C18 reverse-phase high-performance liquid chromatography
(HPLC) and its molecular mass was measured by mass spectrometry.
For chemical modiﬁcation with 5-carboxytetramethylrhodamine
succinimidyl ester (Invitrogen, Carlsbad, CA, USA), one volume of
the easily-labeled relaxin-3 solution (1.5 mM in 100 mM phosphate
buffer, pH 7.4) was mixed with 1/3 volume of the labeling reagent
(20 mM in dimethyl sulfoxide). After incubation at room temperature
for 1–2 h, the reaction mixture was acidiﬁed to pH 3.0 using
triﬂuoroacetic acid and subjected to HPLC. The labeled relaxin-3 was
eluted from a C18 reverse-phase column by an acidic acetonitrile
gradient, manually collected, lyophilized and analyzed by mass
spectrometry.
2.4. Fluorescent microscopic observation
The stable HEK293T cells inducibly coexpressing RXFP3-Luc and
RXFP3-EGFP were seeded into 35-mm glass-bottomed dishes and
grown to approximately 60% conﬂuence. Thereafter, doxycycline was
added to a ﬁnal concentration of 20 ng/ml and the cells were continu-
ously cultured overnight. Thereafter, the cells were changed into
the assay solution (serum-free DMEM medium plus 1% bovine
serum albumin) containing 50 nM of the ﬂuorescent dye-labeled
relaxin-3. After continuous culture for 1–2 h, the cells were washed
with the assay solution and observed under a confocal ﬂuorescence
microscope.
2.5. Ligand-binding assays
The stable HEK293T cells inducibly coexpressing RXFP3-Luc and
RXFP3-EGFP were seeded into a 96-well plate and grown to approxi-
mately 60% conﬂuence. Thereafter, doxycycline was added into the
medium to a ﬁnal concentration of 50 ng/ml and the cells were contin-
uously cultured overnight. For the saturation binding assays, the induc-
tionmediumwas removed and the binding solution (serum-freeDMEM
medium plus 1% bovine serum albumin, 200 μl/well) containing
different concentrations of DTPA/Eu3+-labeled R3/I5 tracer [20] was
added. For the competition assays, the binding solution (serum-free
DMEMmedium plus 1% bovine serum albumin, 200 μl/well) containing
4.0 nM of DTPA/Eu3+-labeled R3/I5 tracer and different concentrations
of competitor was added. After binding at 21–22 °C for 2 h, the binding
solution was removed and the cells were washed twice with cold
washing solution (serum-free DMEMmedium, 200 μl/well). Thereafter,
inducer solution (from PerkinElmer, Waltham, MA, USA, 100 μl/well)
was added to dissociate Eu3+ from the DTPA chelator. After shaking
for 15–30 min, the solutions (80 μl/well) were transferred to a white
opaque 384-well plate for time-resolved ﬂuorescence measurement
using a Spectramax M5 plate reader (Molecular Devices, Sunnyvale,
CA, USA). Nonspeciﬁc binding was obtained by competition with
1.0 μMof relaxin-3. The saturation binding datawereﬁtted to hyperbolic
curves, Y = BmaxX / (Kd + X), and the competition binding data were
ﬁtted to sigmoidal curves, Y = 100 / (1 + 10X−logIC50), using SigmaPlot
10.0 software.
2.6. Quantitative receptor internalization assays
The stable HEK293T cells inducibly coexpressing RXFP3-Luc and
RXFP3-EGFP were seeded into a 96-well plate and grown to approxi-
mately 60% conﬂuence. Thereafter, doxycycline was added to a ﬁnal
concentration of 3.5 ng/ml and the cells were continuously cultured
overnight. Thereafter, the induction medium was removed and the
assay solution (serum-free DMEM medium plus 1% bovine serum
albumin) containing different concentrations of peptide was added
(100 μl/well). After continuous culture at 37 °C for 4–5h if not otherwise
mentioned, the assay solutionwas removed and the cellswere detached
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100 μl/well). The living cell suspension (50 μl/well) was then trans-
ferred to a white, opaque 96-well plate. After addition of diluted
substrate solution (50 μl/well, diluted in phosphate-buffered saline),
the bioluminescence was immediately measured using a SpectroMax
M5 plate reader (Molecular Devices). The measured bioluminescence
data were expressed as mean ± SE and ﬁtted to sigmoidal curves,
Y = min + (100 − min) / (1 + 10X−logEC50), using SigmaPlot 10.0
software.3. Results and discussion
3.1. Generation of stable HEK293T cells inducibly coexpressing RXFP3-Luc
and RXFP3-EGFP
To test whether the newly developed NanoLuc reporter could be
used for quantitative measurement of the internalization of RXFP3, we
generated a RXFP3-Luc fusion protein in which the NanoLuc reporter
was fused at the C-terminus of human RXFP3. To visualize the internal-
ization of RXFP3 in the transfected cells, we coexpressed a C-terminally
EGFP-tagged RXFP3 (RXFP3-EGFP) with RXFP3-Luc using a Tet-On
inducible bi-directional promoter that insures equivalent coexpression
of RXFP3-Luc and RXFP3-EGFP in a controllable manner. The tagged
EGFP reporter was also used as a selection marker to generate stable
HEK293T cells coexpressing both RXFP3-Luc and RXFP3-EGFP using
FACS selection. After the coexpression construct and an expression
control vector were transiently cotransfected into HEK293T cells, the
resultant stable cells were generated by two rounds of FACS selection
according to the ﬂuorescence of tagged EGFP reporter and cultured as
a stable cell pool. After these stable cells were induced by doxycycline,
most of them had green ﬂuorescence (from the tagged EGFP reporter)
(Fig. 1); while no green ﬂuorescence was observed without inductionFig. 1. Fluorescent microscopic observation of the coexpression of RXFP3-EGFP and RXFP3-L
overnight and then either treated with red ﬂuorescent dye-labeled relaxin-3 or not, and obser(data not shown), indicating that these cells expressed RXFP3-EGFP
in a controllablemanner. The observed greenﬂuorescencewas predom-
inantly located on the cell membrane (Fig. 1), suggesting that the
C-terminal tag had no detrimental effect on the structural integrity
and intracellular trafﬁcking of RXFP3. To test whether the tagged
RXFP3 could bind relaxin-3 and undergo internalization after ligand
binding, we treated these cells with a red ﬂuorescent dye-labeled
relaxin-3: most of the green ﬂuorescence on the cell membrane
disappeared after treatment with the labeled ligand, meanwhile many
intracellular green dots appeared (Fig. 1), suggesting that the cell mem-
brane RXFP3-EGFP was internalized into intracellular compartments.
Red intracellular dots were also observed in these cells, suggesting
that the labeled relaxin-3 was internalized together with the receptor.
After the green ﬂuorescent image and the red ﬂuorescent image
were merged, many yellow dots were observed (Fig. 1), suggesting
that these internalized dots contained the green RXFP3-EGFP and the
red labeled relaxin-3. Some red dots were also observed in the merged
image (Fig. 1), suggesting that these internalized dots contained
the colorless RXFP3-Luc and the red labeled relaxin-3. Our later
bioluminescent assay also conﬁrmed the inducible expression of
RXFP3-Luc in these stable cells (Fig. 3A). Thus,we successfully generated
stable HEK293T cells inducibly coexpressing both RXFP3-Luc and
RXFP3-EGFP, based on transient transfection and subsequent FACS
selection. This approach could also be used to generate other stable
cells quickly.3.2. Ligand-binding potency of the C-terminally tagged RXFP3
Our above results demonstrated qualitatively that the C-terminally
tagged RXFP3 retained the ligand binding ability. Next, its ligand
binding potency was measured quantitatively via receptor-binding
assays using a DTPA/Eu3+-labeled R3/I5 tracer [20]. As shown in Fig. 2A,uc in the stable HEK293T cells. The stable HEK293T cells were induced by doxycycline
ved under a confocal microscope.
Fig. 2. (A) Saturation binding of the DTPA/Eu3+-labeled R3/I5 to the stable HEK293T cells
after doxycycline induction.Nonspeciﬁc bindingwas obtained by competitionwith 1.0 μM
of relaxin-3. The speciﬁc binding data were expressed asmeans± SE (n=3) and ﬁtted to
a one-site saturation binding curve Y = BmaxX / (Kd + X) using SigmaPlot 10.0 software.
Upper left inner panel, the Scatchard plot of the speciﬁc binding. Lower right inner
panel, the total binding and nonspeciﬁc binding of the tracer with the stable cells with
or without doxycycline induction. (B) Competition receptor-binding of mature and
single-chain relaxin-3s to the stable HEK293T cells after doxycycline induction. The
DTPA/Eu3+-labeled R3/I5 concentration used in this assay was 4.0 nM. The normalized
binding data were expressed as means ± SE (n = 3) and ﬁtted to a sigmoidal curve
Y = 100 / (1 + 10X−logIC50) using SigmaPlot 10.0 software.
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ciation constant (Kd) of 3.2 ± 0.8 nM (n= 3) after the stable HEK293T
cells were induced by doxycycline. The present Kd value was similar to
our previous value measured using the same tracer and the untagged
RXFP3 [20], suggesting that the C-terminal tag had nodetrimental effect
on the ligand-binding potency of RXFP3. For the stable HEK293T cells,
the calculated maximum ligand-binding capacity (Bmax) reached
96 ± 11 fmole/well (n = 3), suggesting that the C-terminally tagged
RXFP3 could be efﬁciently trafﬁcked to the cell membrane. For the
cells without doxycycline induction, no speciﬁc binding was detected
(Fig. 2A, the lower left inner panel), suggesting that the expression of
the tagged RXFP3 was under a controllable manner. As the stable
HEK293T cells efﬁciently overexpressed active RXFP3, we also used
them as a receptor source for competition receptor-binding assays:
typical sigmoidal curves were obtained for both two-chain mature
relaxin-3 and its single-chain precursor, with different pIC50 values:
7.92 ± 0.04 for mature relaxin-3 and 5.67 ± 0.09 for the precursor(Fig. 2B). Thus, the stable HEK293T cells also provided a convenient
receptor source to study the interaction of RXFP3 with various
ligands.
3.3. Quantitative RXFP3 internalization assay using the tagged NanoLuc
reporter
To conﬁrm the inducible coexpression of RXFP3-Luc, we measured
theNanoLuc activity after the stable HEK293T cells were induced by dif-
ferent concentrations of doxycycline overnight (Fig. 3A). The measured
bioluminescence increased as the concentration of the inducer
increased, suggesting that RXFP3-Luc was expressed in these stable
cells in a controllable manner. To conﬁrm that the differently tagged
RXFP3s had similar expression levels, we coexpressed RXFP3-HA-Luc
and RXFP3-Flag-EGFP in which an HA-tag and a Flag-tag were inserted
between RXFP3 and the reporter, respectively. As analyzed byWestern
blot (Fig. 3A, the inner panel), the bands of RXFP3-Flag-EGFP and
RXFP3-HA-Luc were detected only after doxycycline induction using
the antibodies against the Flag-tag and the HA-tag, respectively.
However, two bands were detected for both RXFP3-Flag-EGFP and
RXFP3-HA-Luc, which might be caused by partial degradation of
the fusion proteins since the apparent molecular weights of the
lower bands were slightly smaller than the expected values (~79 kDa
for RXFP3-Flag-EGFP and ~72 kDa for RXFP3-HA-Luc). We used the
C-terminally HA-Flag-10 × His-tagged cell membrane iron efﬂux
transporter ferroportin (~68 kDa) transiently overexpressed in
HEK293T cells as a loading control to assess the expression levels
of the differently tagged RXFP3s. The band densities of RXFP3-
Flag-EGFP and RXFP3-HA-Luc were comparable with that of the control
protein (equal loading amount in both Western blots), conﬁrming
that the differently tagged RXFP3s had similar expression levels.
Subsequently, we tested whether RXFP3 internalization could be
measured quantitatively according to the tagged NanoLuc reporter.
After removal of the inducer doxycycline, the measured biolumines-
cence of the intact living cells decreased gradually (Fig. 3B), suggesting
slow spontaneous internalization of RXFP3-Luc in the absence of ligand
binding. After the addition of relaxin-3, the measured bioluminescence
decrease was accelerated signiﬁcantly (Fig. 3B), suggesting that
relaxin-3 binding induced fast internalization of the cell membrane
RXFP3-Luc into intracellular compartments. NanoLuc had a much
lower activity under an acidic environment; thus, the measured
bioluminescence using intact living cells would be signiﬁcantly
decreased after the tagged NanoLuc reporter was sorted into acidic
lysosomes [3]. Our previous work demonstrated that the NanoLuc
substrate furimazine can efﬁciently permeate the cell membrane
and enter intracellular compartments; thus, the bioluminescence
could bemeasured using intact living cells [3]. Thereafter, wemeasured
the dose response of RXFP3-Luc internalization versus relaxin-3 con-
centration (Fig. 3C). The fully active two-chain relaxin-3 induced
RXFP3 internalization in a typical sigmoidal manner, with a calculated
pEC50 value of 8.32±0.04 (n=3) (Fig. 3C). In contrast, the lowactivity
single-chain precursor had almost no effect on RXFP3 internalization.
These results demonstrated that the ligand-induced internalization of
RXFP3 could be measured quantitatively using the tagged NanoLuc
reporter.
3.4. Effect of an inactive RXFP3mutant on ligand-binding and internalization
of wild-type RXFP3
There are reports that someGPCRs formdimers to exert their biolog-
ical functions [21–24]. There is no report of RXFP3 forming dimers. In
the present work, we generated stable HEK293T cells coexpressing a
NanoLuc-tagged wild-type RXFP3 (RXFP3-Luc) and an EGFP-tagged
mutant RXFP4, [E141R]RXFP3-EGFP, in which the highly conserved
extracellular Glu141was replaced by anoppositely charged Arg residue.
The mutant [E141R]RXFP3 cannot be activated by wild-type relaxin-3,
Fig. 3. (A) Doxycycline-dependent expression of RXFP3-Luc in the stable HEK293T cells.
The measured bioluminescence data using intact living cells were expressed as
means ± SE (n = 3). Inner panel, Western blot analysis of RXFP3-HA-Luc and RXFP3-
Flag-EGFP in transiently transfected HEK293T cells. C, control protein: human ferroportin
carrying a tandem HA-Flag-10 × His-tag at the C-terminus (~68 kDa); B, transfected
HEK293T cells without doxycycline induction; and I, transfected HEK293T cells induced
by 50 ng/ml doxycycline overnight. (B) Time course of RXFP3-Luc internalization in the
presence or absence of relaxin-3. The measured bioluminescence data were expressed
as means ± SE (n = 3). (C) Dose response of RXFP3-Luc internalization induced by
relaxin-3 or single-chain relaxin-3 precursor. The relative bioluminescence data
were expressed as means ± SE (n= 3) and ﬁtted by a sigmoidal curve (relaxin-3) Y =
min + (100 − min) / (1 + 10X−logEC50) or a linear curve (relaxin-3 precursor) using
SigmaPlot 10.0 software.
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microscopy (Fig. 4A), [E141R]RXFP3-EGFPwasnormally trafﬁcked to the
cell membrane after inducible expression in HEK293T cells, suggesting
that replacement of Glu141 by Arg had no serious effect on the structural
integrity and intracellular trafﬁcking of RXFP3. After the stable HEK293T
cells were treated with the red ﬂuorescent dye-labeled relaxin-3
(Fig. 4A), [E141R]RXFP3-EGFP still stayed on the cell membrane and
the internalized dots were predominantly red, suggesting that the
labeled relaxin-3 could induce internalization of the colorless RXFP3-
Luc, but could not induce internalization of the green [E141R]RXFP3-
EGFP. Thus, we deduced that the inactive [E141R]RXFP3 had no
detrimental effects on the ligand-induced internalization of the wild-
type RXFP3. To conﬁrm this deduction, we generated transiently
transfected HEK293T cells that coexpressed the inactive [E141R]
RXFP3-Luc and the wild-type RXFP3-EGFP (Fig. 4B). After these cells
were treated by the red ﬂuorescent dye-labeled relaxin-3, the internal-
ized green dots (from RXFP3-EGFP) and the internalized red dots (from
the labeled relaxin-3) were well co-localized, suggesting that only the
wild-type RXFP3-EGFP was internalized with the labeled relaxin-3.
Thus, the presence of the inactive mutant RXFP3 seemed to have no
effect on the ligand-binding and internalization of the wild-type
RXFP3.
To test quantitatively whether the inactive mutant RXFP3 affected
the ligand-binding potency of the wild-type RXFP3, we carried out a
saturation receptor-binding assay using DTPA/Eu3+-labeled R3/I5 as a
tracer. As shown in Fig. 5A, a typical saturation binding curve was
obtained, with a calculated Kd of 2.8 ± 0.7 nM (n = 3), which was
similar to the measured Kd value (3.2 ± 0.8 nM, n = 3) without the
presence of the mutant RXFP3. Thus, the presence of the inactive
mutant RXFP3 had no effect on the ligand-binding potency of the
wild-type RXFP3. To test quantitatively whether the inactive RXFP3
mutant affected internalization of the wild-type RXFP3, we measured
the ligand-induced RXFP3 internalization using the tagged NanoLuc
reporter (Fig. 5B). The internalization curves of RXFP3-Luc induced
by relaxin-3 in the presence of the inactive [E141R]RXFP3-EGFP or
the wild-type RXFP3-EGFP were quite similar, with calculated pEC50
values of 8.34 ± 0.05 (presence of [E141R]RXFP3-EGFP) and 8.32 ±
0.04 (presence of RXFP3-EGFP), respectively. In contrast, no biolumi-
nescence decrease could be measured for the cells coexpressing
[E141R]RXFP3-Luc and RXFP3-EGFP (Fig. 5B, inner panel), conﬁrming
that the inactive RXFP3 could not undergo ligand-induced internaliza-
tion. Thus, the presence of the inactive mutant RXFP3 had no effect
on the ligand-induced internalization of the wild-type RXFP3,
suggesting that the wild-type RXFP3 and the mutant RXFP3 worked
independently.
3.5. Application of the NanoLuc-based internalization assay to other cell
membrane receptors
In the presentwork,we demonstrated that the ligand-induced inter-
nalization of RXFP3 could be measured quantitatively using the tagged
NanoLuc reporter. Once the internalized receptor was sorted into acidic
lysosomes, the measured bioluminescence of the tagged NanoLuc
reporter was signiﬁcantly decreased because of its pH sensitivity
when assayed using the intact living cells. GPCRs are the largest group
of cell membrane receptors and play important biological functions.
So far, there are over one hundred orphan GPCRs whose endogenous
ligands remain unknown. Deorphanization of these orphan GPCRs is a
critical step to elucidate their biological functions. Ligand-binding
induced internalization is a general phenomenon to GPCRs and is
independent of the knowledge of intracellular signaling pathways that
are unknown for orphanGPCRs. Thus, thepresentNanoLuc-based quan-
titative internalization assay could be applied to deorphanization of
some orphan GPCRs. The present assay could be easily adapted to high
throughput screening and is thus suitable for screening large compound
libraries. For GPCRs with known ligands, the present quantitative
Fig. 4. (A) Fluorescentmicroscopic observation of the inducible coexpression of [E141R]RXFP3-EGFP and RXFP3-Luc in the stableHEK293T cells. The stable HEK293T cells were induced by
doxycycline overnight and then either treatedwith red ﬂuorescent dye-labeled relaxin-3 or not and observed under a confocal microscope. (B) Fluorescentmicroscopic observation of the
inducible coexpression of RXFP3-EGFP and [E141R]RXFP3-Luc in the transiently transfected HEK293T cells. The transiently transfected HEK293T cells were induced by doxycycline
overnight and then either treated with red ﬂuorescent dye-labeled relaxin-3 or not and observed under a confocal microscope.
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tions. Internalization of other cell membrane receptors could also be
assayed using the NanoLuc-based approach once the internalized
receptors are sorted into acidic intracellular compartments.Acknowledgments
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